Showing results (581-590 of 596) with videos related to

Sort By:
Pageof 60
Cancer Research|May 5, 2018
SETD2 Haploinsufficiency for Microtubule Methylation Is an Early Driver of Genomic Instability in Renal Cell CarcinomaYun-Chen Chiang, In-Young Park, Esteban A Terzo, et al.
Journal of Medicinal Chemistry|March 12, 2024
Discovery and Optimization of Selective Brain-Penetrant EBP Inhibitors that Enhance Oligodendrocyte FormationRuth Dorel, Dawei Sun, Nicholas Carruthers, et al.
Current Medical Research and Opinion|December 15, 2010
Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RAJosef S Smolen, Maarten Boers, Eric C Abadie, et al.
Aging Clinical and Experimental Research|January 10, 2016
Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)Cyrus Cooper, Thomas Bardin, Maria-Luisa Brandi, et al.
Science Advances|April 3, 2021
A cytoskeletal function for PBRM1 reading methylated microtubulesMenuka Karki, Rahul K Jangid, Ramakrishnan Anish, et al.
Blood Advances|October 8, 2025
Polatuzumab vedotin in CNS lymphoma: proof-of-concept study for blood-brain barrier penetrationLei Gao, Avyakta Kallam, Geoffrey Shouse, et al.
Molecular Cancer Therapeutics|April 20, 2013
DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphomaDongwei Li, Kirsten Achilles Poon, Shang-Fan Yu, et al.
Molecular Psychiatry|February 11, 2018
Uncoupling the widespread occurrence of anti-NMDAR1 autoantibodies from neuropsychiatric disease in a novel autoimmune modelHong Pan, Bárbara Oliveira, Gesine Saher, et al.
Leukemia|July 3, 2010
Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphomaA G Polson, M Williams, A M Gray, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2019
Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian CancerDavid E Gerber, Jeffrey R Infante, Michael S Gordon, et al.
Pageof 60